Table of Contents
- Overview
- Symptoms
- Treatment
- Prevention
- Images
Alopecia in women; Baldness - female; Hair loss in women; Androgenetic alopecia in women
Treatment
The
The only drug or medication approved by the United States Food and Drug Administration (FDA) to treat female pattern baldness is minoxidil, used on the scalp.
- For women, the 2% concentration is recommended.
- Minoxidil may help hair grow in 20% to 25% of women. In most women it may slow or stop hair loss.
- Treatment is expensive, because you must continue to use the medication. Hair loss starts again when you stop using minoxidil.
In women who do not respond to minoxidil, oral spironolactone may be added.
- Spironolactone may help women whose hair loss is caused by too much male hormones (androgens). This drug is not FDA-approved for female baldness.
- It can cause increased potassium levels in the blood, and cannot be used in people with kidney failure or who are pregnant.
Hair transplants remove tiny plugs of hair from areas where hair is thicker, and place them in areas that are balding. This can cause minor scarring where the hair is removed, and carries a slight risk for skin infection. Many transplantation sessions are usually needed, which can be expensive. However, the results are often excellent and permanent.
The use of hair implants made of artificial fibers was banned by the FDA because of the high rate of infection.
Stitching (suturing) hair pieces to the scalp is not recommended. It can result in scars, infections, and
Hair weaving, hairpieces, or a change in hairstyle may disguise hair loss and improve your appearance. This is often the least expensive and safest way to deal with female pattern baldness.
Support Groups
Expectations (prognosis)
Female pattern
Complications
Complications are psychological
Calling your health care provider
Call your health care provider if you experience
Images
Previous Section
Review Date: 03/10/2010
Reviewed By: Linda J. Vorvick, MD, Medical Director, MEDEX Northwest Division of
Physician Assistant Studies, University of Washington, School of
Medicine; and Roy Colven, MD, Dermatologist, Associate Professor of
Medicine, University of Washington Medical School, Seattle,
Washington. Also reviewed by David Zieve, MD, MHA, Medical
Director, A.D.A.M., Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)
